New Medications

Resource Center

Featured

Research Summary
Research Summary
10/15/2024
Miranda Manier, BA
Two phase 3 randomized trials evaluated the efficacy of risankizumab in patients with moderately to severely active ulcerative colitis. The results show significantly higher remission rates with...
10/15/2024
FDA Alert
FDA Alert
09/30/2024
Miranda Manier, BA
Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.
09/30/2024
Conference Coverage
Conference Coverage
03/13/2024

Anthony Calabro, MA

Anthony Calabro, MA
The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
03/13/2024

Interactive Features

Medication Prescribing
Medication Prescribing
08/13/2016
Joshua is an 80-year-old man who had been stable on coumadin for 12 months, consistently demonstrating an INR of 2.2 to 3.1. Today, Joshua presented with an INR of 21.4, which results in immediate admission...
08/13/2016
Oral and Perioral Lesions
Oral and Perioral Lesions
03/03/2016
We previously met Zeke, a 19-year-old college student with a history of recurrent aphthous ulcers.
03/03/2016
Diabetes
Diabetes
09/22/2014
We previously met Louis, a healthy 68-year-old male who currently takes no medications but has been reluctant to start statin use due to concerns that it may cause dementia. Today, you receive a call from...
09/22/2014

Clinical Insights

Gastroenterology
Gastroenterology
09/12/2020
In this 7-minute video, Dr Hudesman recaps his presentation on new and emerging therapeutic targets in IBD.
09/12/2020
Inflammatory Bowel Disease
Inflammatory Bowel Disease
07/25/2020
David Rubin, MD, review his talk at the virtual AIBD 2020 regional meeting July 25 on new and emerging therapeutics for inflammatory bowel disease.
07/25/2020
NAFLD
NAFLD
07/15/2020
He discusses his session on endocrine pathways and therapeutic options for patients with nonalcoholic fatty liver disease, which he presented at Harvard University’s 21st Annual Symposium on NAFLD.
07/15/2020
new medications
new medications
03/08/2015
In this article Michael J. Bloch, MD, writes about the potential use of a polypill for cardiovascular disease prevention and discusses how the results of recent research supports the potential use in the...
03/08/2015